

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Biologics Evaluation and Research (CBER)  
189th Meeting of the Vaccines and Related Biological Products Advisory  
Committee**

**May 22, 2025**

**Voting Question**

---

For the 2025-2026 Formula of COVID-19 vaccines in the U.S., does the committee recommend a monovalent JN.1-lineage vaccine composition?

**Please vote “Yes” or “No” or “Abstain”**

**Discussion Topic**

---

Based on the evidence presented, please discuss considerations for the selection of JN.1 and/or a specific JN.1-lineage strain for COVID-19 vaccines (2025-2026 Formula) to be used in the U.S.